Document Type: Original Article

Authors

Synthesis and Molecular Simulation Laboratory, Chemistry Department, Pars Isotope Company, P.O. Box: 1437663181, Tehran, Iran

Abstract

Design of novel antipsoriatic drugs based on the medicinal compound Tazarotene is the main purpose of the present study. Firstly, the molecular structures of Tazarotene and its derivatives (F, Cl, CH3, OCH3, COOH, OH, NH2 and CF3) were optimized using density functional theory (DFT) at B3LYP/6-311++G (d, p) computational method. Then, the optimized molecules were docked into the active site of the retinoic acid receptors. The molecular docking analyses revealed that, the Tazarotene derivatives with COOH, CF3 and OCH3 substituents can make strongest complexes with RAR-alpha, RAR-beta and RAR-gamma, respectively. Based on the physicochemical properties calculations, it was cleared that the CF3 derivative of Tazarotene has better properties (receptor-ligand interaction efficiency, lipophilicity and skin permeation) compared with that of the Tazarotene.

Graphical Abstract

Keywords

[1]. Kim W.B.,  Jerome D., Yeung J. Can. Fam. Physician., 2017, 63: 278

[2]. Winterfield L.S., Menter A., Gordon K., Gottlieb A. Ann. Rheum. Dis., 2005, 64:ii 87

[3]. Verallo-Rowell V.M., Katalbas S.S., Evangelista M.T., Dayrit J.F. Curr. Dermatol. Rep., 2018,7: 24

[4]. Lebwohl M., Ali S. J. Am. Acad. Dermatol., 2001,45: 487

[5]. Saurat J.H. J. Am. Acad. Dermatol., 1999,41: S2-6

[6]. Van de Kerkhof  P.C. Dermatol. Ther, 2006,19: 252

[7]. Khalil S., Bardawil T., Stephan C., Darwiche N., Abbas O., Kibbi A.G., Nemer G.,  Kurban M. J. Dermatolog. Treat., 2017, 28: 684

[8]. Guenther L.C. Am. J. Clin. Dermatol., 2003, 4: 197

[9]. Heath M.S., Sahni D.R., Curry Z.A., Feldman S.R. Expert. Opin. Drug. Metab. Toxicol., 2018,14: 919

[10]. Del Rosso J.Q., Kircik L., Lin T., Pillai R. J. Clin .Aesthet. Dermatol., 2019,12: 11

[11]. Khaledi M., Atiq H.Z.Q., Chamkouri N., Mojaddami A. Iran. Chem. Commun., 2019, 7: 480

[12]. Nabati M. Chem. Methodol., 2018, 2: 223

[13]. Nabati M. Iran. Chem Commun., 2019, 7: 324

[14]. Nabati M., Sabahnoo H. J. Med. Chem. Sci., 2019,2: 118

[15]. Nabati M., Kermanian M., Mohammadnejad-Mehrabani H., Kafshboran H.R., Mehmannavaz M., Sarshar S. Chem. Methodol., 2018,2: 128

[16]. Nabati M. Asian J. Green Chem., 2019,3: 258

[17]. Nabati M. J. Phys. Theor. Chem. IAU Iran., 2017,14: 283

[18]. Nabati M. Chem. Methodol., 2017, 1, 121.

[19]. Nabati M. J. Phys. Theor. Chem. IAU Iran., 2017, 14: 49

[20]. Nabati M., Mahkam M., Atani Y.G. J. Phys. Theor. Chem. IAU Iran., 2016, 13: 35

[21]. Nabati M., Mahkam M. Org. Chem. Res., 2016,2: 70

[22]. Nabati M., Sabahnoo H., Lohrasbi E., Mazidi M. Chem. Methodol., 2019, 3: 383

[23]. Mandal D., Maity R., Beg H., Salgado-Moran G., Misra A. Mol. Phys., 2018, 116: 515

[24]. Meenakshi R. J. Mol. Struct., 2017, 1127: 694

[25]. Mishra V.R., Sekar N. J. Flouresc., 2017, 27: 1101

[26]. Rajan V.K., Muraleedharan K. Food Chem., 2017, 220: 93

[27]. Butina D., Segall M.D., Frankcombe K. Drug Discov. Today., 2002, 7: S83

[28]. Di L. AAPS J., 2015, 17: 134

[29]. Nabati M. J. Med. Chem. Sci., 2020,3: 22

[30]. Yamashita F., Hashida M. Pharmacokinet., 2004, 19: 327

[31]. Leadbetter M.R., Adams S.M., Bazzini B., Fatheree P.R., Karr D.E., Krause K.M., Lam B.M.T., Linsell M.S., Nodwell M.B., Pace J.L., Quast K., Shaw J.P., Soriano E., Trapp S.G., Villena J.D., Wu T.X., Christensen B.G., Judice J.K. J. Antibiot., 2004, 57: 326